Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) shares dropped 3.5% during mid-day trading on Monday . The company traded as low as C$16.41 and last traded at C$16.76. Approximately 4,611,683 shares were traded during trading, an increase of 1,906% from the average daily volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Stock Down 3.5 %
The company has a current ratio of 11.93, a quick ratio of 11.02 and a debt-to-equity ratio of 2.69. The company has a 50 day simple moving average of C$16.76. The company has a market cap of C$2.15 billion and a price-to-earnings ratio of -11.32.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Market Cap Calculator: How to Calculate Market Cap
- The Charles Schwab Company Can Hit New Highs
- What Are the U.K. Market Holidays? How to Invest and Trade
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
